Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics, Inc. (PTCT) Form 144 filing: An insider has notified intent to sell up to 10,739 common shares through Fidelity Brokerage around 05 Aug 2025. Based on the stated aggregate market value of $555,662.71, the proposed sale is priced near $51.75 per share. The shares were obtained via restricted-stock vesting on 01 Aug 2025 and will be sold on Nasdaq.
The block represents roughly 0.014 % of PTCT’s 79.26 million shares outstanding, implying negligible dilution or liquidity impact. While the monetary size is modest for a company of PTCT’s scale, the filing indicates near-term insider profit-taking shortly after vesting, a datapoint some investors watch as a sentiment signal.
PTC Therapeutics, Inc. (PTCT) filed a Form 144 signaling an affiliate’s intent to sell up to 2,516 common shares through Fidelity Brokerage Services on or about 15 July 2025. The shares were recently acquired via restricted-stock vesting on 14 July 2025 and have an aggregate market value of approximately $124,435, implying a reference price near $49.45 per share. With 79.26 million shares outstanding, the planned disposition represents less than 0.01 % of total equity—too small to affect liquidity, control, or valuation. No additional sales by this insider have occurred within the past three months, and the filing provides no further operational or financial commentary.